NCT04323436 - Study of Capmatinib and Spartalizumab/Placebo in Advanced NSCLC Patients With MET Exon 14 Skipping Mutations | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 19, 2020

Primary Completion Date

December 14, 2022

Study Completion Date

January 26, 2023

Conditions

Carcinoma, Non-Small-Cell Lung

Interventions

DRUG

Spartalizumab

Concentrate for solution for infusion

DRUG

Capmatinib

Film-coated tablet

DRUG

spartalizumab placebo

dextrose 5% in water (D5W) for infusion

Trial Locations (15)

3000

Novartis Investigative Site, Leuven

13125

Novartis Investigative Site, Berlin

40138

Novartis Investigative Site, Bologna

46014

Novartis Investigative Site, Valencia

50937

Novartis Investigative Site, Cologne

59000

Novartis Investigative Site, Lille

69495

Novartis Investigative Site, Pierre-Bénite

70839

Novartis Investigative Site, Gerlingen

72076

Novartis Investigative Site, Tübingen

75014

Novartis Investigative Site, Paris

02114

Massachusetts General Hospital Liver and Kidney TX, Boston

H4A 3J1

Novartis Investigative Site, Montreal

589 8511

Novartis Investigative Site, Ōsaka-sayama

03080

Novartis Investigative Site, Seoul

08036

Novartis Investigative Site, Barcelona